Get the Stockscreener App
2.6214
4.09%
-0.0486
Sutro Biopharma Inc stock is traded at $2.6214, with a volume of 162.22K.
It is down -4.09% in the last 24 hours and down -29.65% over the past month.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.
See More
Previous Close:
$2.67
Open:
$2.66
24h Volume:
162.22K
Relative Volume:
0.26
Market Cap:
$220.16M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-1.0613
EPS:
-2.47
Net Cash Flow:
$-115.93M
1W Performance:
-25.77%
1M Performance:
-29.65%
6M Performance:
-43.59%
1Y Performance:
-4.80%
1-Day Range:
$2.55
$2.7677
1-Week Range:
$2.55
$3.46
52-Week Range:
$2.13
$6.13
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| STRO | 2.62 | 220.16M | 153.73M | -106.79M | -115.93M | -2.47 |
| VRTX | 447.96 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.12 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.39 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.31 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.70 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
Sutro Biopharma Advances Pipeline Amid Financial Losses - MSN
HC Wainwright Estimates Sutro Biopharma Q2 Earnings - Defense World
HC Wainwright Raises Earnings Estimates for Sutro Biopharma - Defense World
Brokers Set Expectations for Sutro Biopharma FY2024 Earnings - MarketBeat
HC Wainwright Reaffirms Buy Rating for Sutro Biopharma (NASDAQ:STRO) - Defense World
Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know - MSN
Analysts Set Expectations for Sutro Biopharma Q2 Earnings - MarketBeat
Sutro Biopharma's (STRO) Buy Rating Reiterated at HC Wainwright - MarketBeat
A Glimpse Into The Expert Outlook On Sutro Biopharma Through 5 Analysts - Benzinga
Sutro Biopharma FY2024 EPS Forecast Increased by Wedbush - MarketBeat
Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Baillie Gifford & Co. - MarketBeat
Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates - MSN
Sutro Biopharma earnings beat by $0.14, revenue fell short of estimates - Investing.com UK
Sutro Biopharma Inc (STRO) Q3 2024 Earnings: Revenue Misses Esti - GuruFocus.com
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - The Manila Times
Sutro Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Sutro Biopharma Reports 56% Response Rate in Cancer Trial, Plans 3 New Drug Applications | STRO Stock News - StockTitan
BioSpace Announces 2025 Best Places to Work in Biopharma - BioSpace
Caribou Biosciences (NASDAQ:CRBU) vs. Sutro Biopharma (NASDAQ:STRO) Financial Analysis - Defense World
Sutro Biopharma (NASDAQ:STRO) shareholders are up 16% this past week, but still in the red over the last three years - Simply Wall St
Vanguard Group Inc's Strategic Acquisition in Sutro Biopharma Inc - GuruFocus.com
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference - The Manila Times
Sutro Biopharma begins trial of acute myeloid leukaemia treatment in children - Clinical Trials Arena
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Buy” from Brokerages - Defense World
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.13 Average PT from Brokerages - MarketBeat
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML - The Manila Times
Sutro Biopharma's SWOT analysis: stock poised for growth amid clinical progress - Investing.com
The Manufacturers Life Insurance Company Buys 7,082 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago - Yahoo Finance
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Cubist Systematic Strategies LLC - MarketBeat
Sutro Biopharma: Post ESMO Selloff, Does Their Strategy In FRα Remain Viable? - Seeking Alpha
Sutro Biopharma Inc Inc. (STRO) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
Algert Global LLC Reduces Stake in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
AQR Capital Management LLC Boosts Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
AQR Capital Management LLC Buys 247,694 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Sutro Biopharma (NASDAQ:STRO) - Defense World
Sutro Biopharma (NASDAQ:STRO) & Palisade Bio (NASDAQ:PALI) Head-To-Head Contrast - Defense World
Piper Sandler sustains Overweight rating on Sutro Biopharma shares By Investing.com - Investing.com Canada
Sutro Biopharma retains stock target with Buy rating on key advancements - Investing.com Canada
Peeling Back The Layers: Exploring Sutro Biopharma Through Analyst Insights - Benzinga
Sutro Biopharma (NASDAQ:STRO) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Revenues Working Against Sutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Following 25% Dive - Simply Wall St
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Sold by Dimensional Fund Advisors LP - MarketBeat
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum - The Manila Times
After-Market Gains For Sutro Biopharma (STRO) Following An Investor Webcast - Stocks Telegraph
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $12.13 Average Price Target from Analysts - MarketBeat
Sutro Biopharma, Inc. (NASDAQ:STRO) Shares Bought by ProShare Advisors LLC - Defense World
Cubist Systematic Strategies LLC Trims Stock Position in Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Millennium Management LLC Has $12.78 Million Holdings in Sutro Biopharma, Inc. (NASDAQ:STRO) - MarketBeat
It would be worthwhile to take a closer look at Sutro Biopharma Inc (STRO) - US Post News
Sutro Biopharma Inc Stock (STRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sutro Biopharma Inc Stock (STRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chung Jane | PRESIDENT AND COO |
Aug 09 '24 |
Option Exercise |
0.00 |
18,750 |
0 |
60,951 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
May 01 '24 |
Option Exercise |
0.00 |
2,500 |
0 |
32,622 |
| Srinivasan Venkatesh | CHIEF TECH OP OFFICER |
Apr 11 '24 |
Option Exercise |
0.00 |
21,250 |
0 |
37,704 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 05 '24 |
Option Exercise |
0.00 |
8,750 |
0 |
76,060 |
| NEWELL WILLIAM J | CEO |
Mar 05 '24 |
Option Exercise |
0.00 |
18,750 |
0 |
226,893 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 05 '24 |
Option Exercise |
0.00 |
8,750 |
0 |
109,843 |
| NEWELL WILLIAM J | CEO |
Mar 04 '24 |
Option Exercise |
0.00 |
31,125 |
0 |
219,248 |
| FITZPATRICK LINDA A | CHIEF PEOPLE & COMM. OFFICER |
Mar 04 '24 |
Option Exercise |
0.00 |
9,125 |
0 |
71,049 |
| Chung Jane | PRESIDENT AND COO |
Mar 04 '24 |
Option Exercise |
0.00 |
7,875 |
0 |
44,410 |
| ALBINI EDWARD C | CFO AND SECRETARY |
Mar 04 '24 |
Option Exercise |
0.00 |
9,125 |
0 |
104,565 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):